Inactive Instrument

eSense-Lab Ltd

ESE

AU000000ESE9

Biotechnology & Medical Research

Esense Announces the Cessation of Galit Assaf as Director Effective from 8 November 2019

November 15, 2019 at 12:50 pm IST

ESENSE announced the cessation of Galit Assaf as director effective from 8 November 2019.

Latest news about eSense-Lab Ltd

Esense-Lab Ltd Appoints Maayan Bar as External Directors	06/21/06	CI
ESense Lab : ESsense-lab Applies to Delist from Australian Bourse	25/21/25	MT
ESense lab : Widens 2020 Loss as Revenue Falls, Financial Expenses Jump	01/21/01	MT
Esense-Lab Ltd Reports Earnings Results for the Full Year Ended December 31, 2020	01/21/01	CI
ESense-Lab Limited Provides Further Update on Research Agreement with Israeli MOH	17/21/17	CI
Esense lab : Secures Funds for Operational Expenditure, Working Capital	29/20/29	MT
ESense-Lab Ltd Announces Executive Changes	04/20/04	CI
ESense lab : Moves Toward Commercialization of Alcohol-Free Sanitizer	27/20/27	MT
ESense-Lab Ltd Provides Update on Research Agreement with Israeli Ministry of Health	27/20/27	CI
Esense-Lab Ltd Reports Earnings Results for the Half Year Ended June 30, 2020	01/20/01	CI
ESense-Lab Ltd Signs A Research Agreement with the Israeli Ministry of Health to Commence A Joint Research Project	31/20/31	CI
Esense-Lab Ltd Announces Change in Registered Office Address	03/20/03	CI
ESense-Lab Ltd Announces Executive Changes, Effective July 6, 2020	03/20/03	CI
ESense-Lab Ltd Announces Board Changes	02/20/02	CI
ESense-Lab Ltd announced that it has received AUD 1.145 million in funding from Everblu Capital Pty. Ltd.	24/20/24	CI
ESense-Lab Limited Enters into Binding Joint Venture Agreement with Sassey Pty Ltd	18/20/18	CI
ESense-Lab Limited Signs JV Agreement with Anc Enterprises Ltd to Develop and Sell New Products	15/20/15	CI
ESense-Lab Ltd Announces Resignation of Amit Edri, Director	09/20/09	CI
ESense-Lab Ltd Enters into Letter of Intent with SeaLaria Ltd	28/20/28	CI
ESense-Lab Ltd announced that it expects to receive AUD 1.145 million in funding from Everblu Capital Pty. Ltd.	14/20/14	CI
ESense-Lab Limited Announces Resignation of Mike Edwards as Director	27/20/27	CI
ESense-Lab Ltd Announces Management Changes	06/20/06	CI
Esense-Lab Limited Reports Earnings Results for the Full Year Ended December 31, 2019	02/20/02	CI
ESense-Lab Limited Announces Executive Changes	29/20/29	CI
Esense Announces the Appointment of Dr James Ellingford as Director Effective from 13 January 2020	13/20/13	CI

Esense-Lab Ltd is an Israel-based pharmaceutical technology company. The Company re-engineers cannabis into a virtual plant, namely terpene, a naturally occurring chemical compounds that generate the flavor and fragrance synthesized by plants. Tarpene can be used both for medicinal purposes and for the production of cannabis-based consumer products. The Company mainly serves the legal cannabis and para-cannabis markets. It also serves the: e-liquid market; pharmaceuticals market, creating on demand customized profiles and personalized medicine, as well as rare plants market, providing sustainability to rare and sought after plants such as ginseng and saffron. Its cannabis terpenes address the cannabis edibles, e-liquids and energy drinks, as well as the essential oils markets.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+22.15%	4.66TCr
LONZA GROUP AG	+45.43%	4.17TCr
IQVIA HOLDINGS INC.	-2.37%	4.12TCr
ALNYLAM PHARMACEUTICALS, INC.	+33.84%	3.24TCr
CELLTRION, INC.	-6.35%	2.81TCr
ICON PUBLIC LIMITED COMPANY	+20.42%	2.82TCr
UNITED THERAPEUTICS CORPORATION	+48.83%	1.45TCr
MEDPACE HOLDINGS, INC.	+45.00%	1.37TCr
BIO-TECHNE CORPORATION	+0.06%	1.22TCr

Other Biotechnology & Medical Research

eSense-Lab Ltd

Equities

ESE

AU000000ESE9

Biotechnology & Medical Research

Esense Announces the Cessation of Galit Assaf as Director Effective from 8 November 2019

Latest news about eSense-Lab Ltd

Chart eSense-Lab Ltd

Company Profile

Sector Other Biotechnology & Medical Research